Curr. Treat. Options in Oncol. (2017) 18: 57 DOI 10.1007/s11864-017-0493-x Letter to the Editor Letter to the Editor: Implications of BRAF Mutations in dMMR Colorectal Cancers Steven Sorscher, MD Address Wake Forest School of Medicine, Oncology Division, Medical Center Blvd, Winston- Salem, NC, 27157, USA Email: firstname.lastname@example.org Published online: 10 August 2017 * Springer Science+Business Media, LLC 2017 This comment refers to the article available at http://dx.doi.org/10.1007/s11864-017-0453-5 Keywords dMMR BRAF Checkpoint I I Dear Editor, I appreciated the recently published “BRAF-Mutated Colorectal Cancer: What is the Optimal Strategy for Treatments?” . The authors appropriately note that immune checkpoint inhibitor therapy has shown very promising results for patients with tumors harboring dMMR. They suggest that such therapy might prove effective for patients with dMMR associated with a BRAF mutation but support this possibility with two references, one that did not distinguish response rates between pa- tients with dMMR tumors associated with a BRAF mutation and those not associated with a BRAF mutation. For the second reference (an abstract concerning an ongoing study), they note “clinical activity was observed regardless of the BRAF and KRAS mutational status mutational statuses and PDL-1 expression.” However, the 25% investigator-determined re- sponse rate apparently involved
Current Treatment Options in Oncology – Springer Journals
Published: Aug 10, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera